[Assessment tools for systemic lupus erythematosus].
Assessment-Tools für den systemischen Lupus erythematodes.
Damage
Disease activity
Fatigue
Low disease activity
Remission
Journal
Zeitschrift fur Rheumatologie
ISSN: 1435-1250
Titre abrégé: Z Rheumatol
Pays: Germany
ID NLM: 0414162
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
accepted:
26
02
2023
medline:
15
6
2023
pubmed:
16
5
2023
entrez:
15
5
2023
Statut:
ppublish
Résumé
A systematic assessment is critical for taking advantage of the current options for optimizing systemic lupus erythematosus (SLE) management. Without regular SLE activity measurements, treat to target and remission are empty words, and the EULAR recommendations therefore insist on these assessments. They rely on activity scores, such as SLEDAI, ECLAM and BILAG or more recently, EasyBILAG and SLE-DAS. Assessment is completed by organ-specific measurement methods and the evaluation of damage. In the study setting the classification criteria and combined endpoints for clinical testing are crucial, as is measurement of the quality of life. This review article provides an overview of the current state of SLE assessments. Ein systematisches Assessment ist entscheidend, um die heutigen Möglichkeiten eines optimalen SLE(systemischer Lupus erythematodes)-Managements zu nützen. Ohne regelmäßige Aktivitätsmessung sind Treat-to-Target und Remission leere Begriffe, und die Empfehlungen der EULAR (European League Against Rheumatism) bestehen deshalb auf diesen Messungen. Sie basieren auf Aktivitätsscores wie SLEDAI (Systemic Lupus Erythematosus Disease Activity Index), ECLAM (European Consensus Lupus Activity Measurement) und BILAG (British Isles Lupus Assessment Group) oder neuer EasyBILAG und SLE-DAS (Disease Activity Score). Dazu kommen organbezogene Messmethoden und die Evaluation des Schadens. Im Studiensetting sind die Klassifikationskriterien und kombinierte Endpunkte für klinische Prüfungen entscheidend sowie die Messung der Lebensqualität. Dieser Review-Artikel gibt einen Überblick über den aktuellen Stand des SLE-Assessments.
Autres résumés
Type: Publisher
(ger)
Ein systematisches Assessment ist entscheidend, um die heutigen Möglichkeiten eines optimalen SLE(systemischer Lupus erythematodes)-Managements zu nützen. Ohne regelmäßige Aktivitätsmessung sind Treat-to-Target und Remission leere Begriffe, und die Empfehlungen der EULAR (European League Against Rheumatism) bestehen deshalb auf diesen Messungen. Sie basieren auf Aktivitätsscores wie SLEDAI (Systemic Lupus Erythematosus Disease Activity Index), ECLAM (European Consensus Lupus Activity Measurement) und BILAG (British Isles Lupus Assessment Group) oder neuer EasyBILAG und SLE-DAS (Disease Activity Score). Dazu kommen organbezogene Messmethoden und die Evaluation des Schadens. Im Studiensetting sind die Klassifikationskriterien und kombinierte Endpunkte für klinische Prüfungen entscheidend sowie die Messung der Lebensqualität. Dieser Review-Artikel gibt einen Überblick über den aktuellen Stand des SLE-Assessments.
Identifiants
pubmed: 37188996
doi: 10.1007/s00393-023-01359-w
pii: 10.1007/s00393-023-01359-w
doi:
Types de publication
English Abstract
Journal Article
Review
Langues
ger
Sous-ensembles de citation
IM
Pagination
361-367Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.
Références
Aringer M, Costenbader K, Daikh D et al (2019) 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis 78:1151–1159
doi: 10.1136/annrheumdis-2018-214819
pubmed: 31383717
Aringer M, Costenbader K, Daikh D et al (2019) 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol 71:1400–1412
doi: 10.1002/art.40930
pubmed: 31385462
pmcid: 6827566
Touma Z, Cervera R, Brinks R et al (2020) Associations among classification criteria items within systemic lupus erythematosus. Arthritis Care Res 72:1820–1826
Tan EM, Cohen AS, Fries JF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277
doi: 10.1002/art.1780251101
pubmed: 7138600
Petri M, Orbai AM, Alarcon GS et al (2012) Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64:2677–2686
doi: 10.1002/art.34473
pubmed: 22553077
pmcid: 3409311
Tedeschi SK, Johnson SR, Boumpas D et al (2018) Developing and refining new candidate criteria for systemic lupus erythematosus classification: an international collaboration. Arthritis Care Res 70:571–581
doi: 10.1002/acr.23317
Aringer M, Brinks R, Dörner T et al (2021) European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. Ann Rheum Dis 80:775–781
Aringer M, Costenbader K, Johnson SR (2022) Assessing the EULAR/ACR classification criteria for patients with systemic lupus erythematosus. Expert Rev Clin Immunol 18:135–144
doi: 10.1080/1744666X.2022.2033617
pubmed: 35076341
Aringer M, Smolen JS (2006) Systemic lupus erythematosus—activity and outcome. ZRheumatol 65(2):103–106, 108–109
Gladman DD, Ibanez D, Urowitz MB (2002) Systemic lupus erythematosus disease activity index 2000. J Rheumatol 29:288–291
pubmed: 11838846
Touma Z, Gladman DD, Su J et al (2018) A novel lupus activity index accounting for glucocorticoids: SLEDAI-2K glucocorticoid index. Rheumatology 57:1370–1376
doi: 10.1093/rheumatology/key103
pubmed: 29688532
Touma Z, Gladman DD, Zandy M et al (2021) Identifying a response for the systemic lupus erythematosus disease activity 2000 glucocorticoid index. Arthritis Care Res 73:1243–1249
doi: 10.1002/acr.24261
Vitali C, Bencivelli W, Isenberg DA et al (1992) Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. II. Identification of the variables indicative of disease activity and their use in the development of an activity score. The European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol 10:541–547
pubmed: 1458710
Isenberg DA, Rahman A, Allen E et al (2005) BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group’s disease activity index for patients with systemic lupus erythematosus. Rheumatology 44:902–906
doi: 10.1093/rheumatology/keh624
pubmed: 15814577
Carter LM, Gordon C, Yee CS et al (2022) Easy-BILAG: a new tool for simplified recording of SLE disease activity using BILAG-2004 index. Rheumatology 61:4006–4015
doi: 10.1093/rheumatology/keab883
pubmed: 35077529
pmcid: 9536795
Jesus D, Matos A, Henriques C et al (2019) Derivation and validation of the SLE Disease Activity Score (SLE-DAS): a new SLE continuous measure with high sensitivity for changes in disease activity. Ann Rheum Dis 78:365–371
doi: 10.1136/annrheumdis-2018-214502
pubmed: 30626657
Petri M, Buyon J, Kim M (1999) Classification and definition of major flares in SLE clinical trials. Lupus 8:685–691
doi: 10.1191/096120399680411281
pubmed: 10568907
van Vollenhoven RF, Mosca M, Bertsias G et al (2014) Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis 73:958–967
doi: 10.1136/annrheumdis-2013-205139
pubmed: 24739325
Fanouriakis A, Kostopoulou M, Alunno A et al (2019) 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 78:736–745
doi: 10.1136/annrheumdis-2019-215089
pubmed: 30926722
Franklyn K, Lau CS, Navarra SV et al (2016) Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Ann Rheum Dis 75:1615–1621
doi: 10.1136/annrheumdis-2015-207726
pubmed: 26458737
Assunção H, Jesus D, Larosa M et al (2022) Definition of low disease activity state based on the SLE-DAS: derivation and validation in a multicentre real-life cohort. Rheumatology 61:3309–3316
doi: 10.1093/rheumatology/keab895
pubmed: 34864894
Van Vollenhoven RF, Bertsias G, Doria A et al (2021) 2021 DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Sci Med 8(1):e000538. https://doi.org/10.1136/lupus-2021-000538
Furie RA, Petri MA, Wallace DJ et al (2009) Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum 61:1143–1151
doi: 10.1002/art.24698
pubmed: 19714615
pmcid: 2748175
Wallace DJ, Kalunian K, Petri MA et al (2014) Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis 73:183–190
doi: 10.1136/annrheumdis-2012-202760
pubmed: 23313811
Houssiau FA, Vasconcelos C, D’cruz D et al (2004) Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum 50:3934–3940
doi: 10.1002/art.20666
pubmed: 15593207
Dall’era M, Cisternas MG, Smilek DE et al (2015) Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort. Arthritis Rheumatol 67:1305–1313
doi: 10.1002/art.39026
pubmed: 25605554
Tamirou F, Lauwerys BR, Dall’era M et al (2015) A proteinuria cut-off level of 0.7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial. Lupus Sci Med 2:e123
doi: 10.1136/lupus-2015-000123
pubmed: 26629352
pmcid: 4654096
Furie R, Rovin BH, Houssiau F et al (2020) Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med 383:1117–1128
doi: 10.1056/NEJMoa2001180
pubmed: 32937045
Rovin BH, Teng YKO, Ginzler EM et al (2021) Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 397:2070–2080
doi: 10.1016/S0140-6736(21)00578-X
pubmed: 33971155
Morand EF, Furie RA, Bruce IN, Vital EM, Dall’era M, Maho E, Pinneda L, Tummala R (2023) Efficacy of anifrolumab across organ domains in patients with moderate to severe SLE: post hoc analysis of pooled data from the TULIP‑1 and TULIP‑2 trials. Lancet Rheumatol 4:e282–e292
Mahmoud K, Zayat AS, Yusof MYM et al (2021) Ultrasound to identify SLE patients with musculoskeletal symptoms who respond best to therapy: The USEFUL longitudinal multicentre study. Rheumatology Rheumatology (Oxford). 60(11):5194–5204
Albrecht J, Taylor L, Berlin JA et al (2005) The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol 125:889–894
doi: 10.1111/j.0022-202X.2005.23889.x
pubmed: 16297185
pmcid: 3928016
Kuhn A, Meuth AM, Bein D et al (2010) Revised Cutaneous Lupus Erythematosus Disease Area and Severity Index (RCLASI): a modified outcome instrument for cutaneous lupus erythematosus. Br J Dermatol 163:83–92
doi: 10.1111/j.1365-2133.2010.09799.x
pubmed: 20394621
Gladman DD, Goldsmith CH, Urowitz MB et al (2000) The systemic lupus international collaborating clinics/American College of Rheumatology (SLICC/ACR) damage index for systemic lupus erythematosus international comparison. J Rheumatol 27:373–376
pubmed: 10685799
Strand V, Simon LS, Meara AS et al (2020) Measurement properties of selected patient-reported outcome measures for use in randomised controlled trials in patients with systemic lupus erythematosus: a systematic review. Lupus Sci Med 7(1):e000373. https://doi.org/10.1136/lupus-2019-000373
Williams-Hall R, Berry P, Williamson N et al (2022) Generation of evidence supporting the content validity of SF-36, FACIT‑F, and LupusQoL, and novel patient-reported symptom items for use in patients with systemic lupus erythematosus (SLE) and SLE with lupus nephritis (LN). Lupus Sci Med 9(1):e000712. https://doi.org/10.1136/lupus-2022-000712
Mcelhone K, Castelino M, Abbott J et al (2010) The LupusQoL and associations with demographics and clinical measurements in patients with systemic lupus erythematosus. J Rheumatol 37:2273–2279
doi: 10.3899/jrheum.091277
pubmed: 20810500
Izadi Z, Gandrup J, Katz PP et al (2018) Patient-reported outcome measures for use in clinical trials of SLE: a review. Lupus Sci Med 5:e279
doi: 10.1136/lupus-2018-000279
pubmed: 30167315
pmcid: 6109821
Bauernfeind B, Aringer M, Prodinger B et al (2009) Identification of relevant concepts of functioning in daily life in people with systemic lupus erythematosus: a patient Delphi exercise. Arthritis Rheum 61:21–28
doi: 10.1002/art.24165
pubmed: 19116959
Leuchten N, Bauernfeind B, Kuttner J et al (2014) Relevant concepts of functioning for patients with systemic lupus erythematosus identified in a Delphi exercise of experts and a literature review. Arthritis Care Res 66:1895–1904
doi: 10.1002/acr.22372
Van Vollenhoven RF, Petri MA, Cervera R et al (2012) Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis 71:1343–1349
doi: 10.1136/annrheumdis-2011-200937
pubmed: 22337213
Chavatza K, Kostopoulou M, Nikolopoulos D et al (2021) Quality indicators for systemic lupus erythematosus based on the 2019 EULAR recommendations: development and initial validation in a cohort of 220 patients. Ann Rheum Dis 80:1175–1182
doi: 10.1136/annrheumdis-2021-220438
pubmed: 34162597